Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 6/20 | 0.46 |
| ▸ | CES2 | O00748 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2418695 | 0.98 | HAO1 (0.48) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL7150300 | 0.91 | HAO1 (0.57) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL2942506 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL21654254 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL7913988 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL2419176 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL4155221 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL21779566 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL1515939 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 | |
| SCHEMBL7145261 | 0.88 | HAO1 (0.61) | HAO1CES1CES2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | HAO1 851/4885CES1 3319/4885CES2 4430/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | HAO1 851/4885CES1 3319/4885CES2 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.